Evidence map›Paper›PMID 35475030›Full record

ArticleBioactive materials2023

Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery.

Jianhua He, Wenli Zhang, Xiaoju Zhou, Fengfei Xu, Jiahui Zou, Qiqi Zhang, Yi Zhao, Hongliang He, Hu Yang, Jianping Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Nanomedicines Against Mitochondrial Dysfunction-Induced Metabolic Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jianhua HeDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.
Wenli ZhangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.
Xiaoju ZhouDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.
Fengfei XuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.
Jiahui ZouDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.
Qiqi ZhangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.
Yi ZhaoSchool of Biomedical Engineering, Sun Yat-sen University, Shenzhen, 518107, PR China.
Hongliang HeState Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, PR China.
Hu YangLinda and Bipin Doshi Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, Rolla, MO, 65401, United States.
Jianping LiuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.
China Pharmaceutical University · CNMissouri University of Science and Technology · USState Key Laboratory of Digital Medical EngineeringSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticle-based therapeutics represent potential strategies for treating atherosclerosis; however, the complex plaque microenvironment poses a barrier for nanoparticles to target the dysfunctional cells. Here, we report reactive oxygen species (ROS)-responsive and size-reducible nanoassemblies, formed by multivalent host-guest interactions between β-cyclodextrins (β-CD)-anchored discoidal recombinant high-density lipoprotein (NP

Indexed as

AtherosclerosisMacrophageReactive oxygen speciesRecombinant high-density lipoproteinSize-reducible nanoassemblies

Identifiers

PMID35475030
PMCPMC9010555
OpenAlexW4225007583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.